uploads/2018/11/Chart-Insys-1.jpg

A Closer Look at Insys Therapeutics’ Performance Year-to-Date

By

Updated

Insys Therapeutics

Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

The company reported EPS of -$0.37 on revenue of $18.35 million in the third quarter.

The chart above compares Insys Therapeutics’ revenues over the last few years and its estimate for 2018.

Article continues below advertisement

Estimate for 2018

Analysts expect Insys Therapeutics to report revenue of $88.42 million in 2018, a 37.1% fall compared to its revenue of $140.69 million in 2017.

Analysts’ recommendations

Analysts expect INSY to rise ~17.9% over the next 12 months. Their consensus recommendation shows a 12-month target price of $9.40 on the stock compared to its price of $7.97 on November 8.

Five analysts are tracking Insys Therapeutics stock. Of these, two have given it “strong buys,” two have given it “buys,” and one has given it a “sell.” The consensus rating for Insys Therapeutics is 2.0, which represents a “strong buy” for value investors.

Market cap

Insys Therapeutics’ market cap is ~$591.7 million as of November 9.

Insys has ~74.2 million outstanding shares. Of these, its free float shares total ~26.8 million, nearly 36.1% of its total outstanding shares. Institutions hold ~21.9% of the company’s total shares, while strategic entities own ~63.9%.

The iShares Micro-Cap ETF (IWC) holds 0.1% in Insys Therapeutics, 0.2% in Cara Therapeutics (CARA), 0.1% in Corbus Pharmaceuticals Holdings (CRBP), and 0.4% in Endocyte (ECYT).

Advertisement

More From Market Realist